BioSpace News Archive

Debiopharm, a Swiss-based global biopharmaceutical company, announced the two winners of the 17th annual JCA Mauvernay Award for breakthrough Japanese oncology research projects in 2 categories: Innovative and/or Disruptive Research – Dr. Shumpei Ishikawa and Translational Research – Dr. Hiromichi Ebi.

CoreBone, a company that produces bioactive, coral-based bone graft material, announced that it has completed an investment round of $3.7 million.

EMD Serono, the Healthcare business sector of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, announced enrollment has been completed in the Phase III EVOLUTION RMS clinical trial program, which is evaluating the efficacy and safety of investigational Bruton’s tyrosine kinase inhibitor evobrutinib in patients with relapsing multiple sclerosis.

Surface Oncology, a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced details about its plan to initiate a randomized Phase 2 clinical study evaluating SRF388, a potential first-in-class antibody against IL-27, in combination with Roche’s atezolizumab and bevacizumab, in patients with treatment-naïve hepatocellular carcinoma.

Starton Therapeutics Inc. announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application No. 16/854,810, covering STAR-LLD, the Company’s continuous delivery lenalidomide program.

First patient has been enrolled in 12-week non-alcoholic fatty liver disease (NAFLD) study

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced it has completed the acquisition of its new research and development center located in Frederick, Md.

Compugen Ltd. (NASDAQ: CGEN), today announced that Compugen is entitled to receive a $6 million milestone payment from AstraZeneca (LSE: AZN) (STO: AZN) (Nasdaq: AZN) triggered by the dosing of the first patient in a Phase 1/2 study evaluating AZD2936, a TIGIT/PD-1 bispecific antibody, in patients with advanced or metastatic non-small cell lung cancer.

NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, announced that new data from two clinical trials evaluating the company’s lead asset NT-I7 will be presented during poster sessions at the Society for Immunotherapy of Cancer annual meeting, to be held both in person in Washington, D.C. and on a virtual platform on November 10-14, 2021.

Boston Pharmaceuticals announced administration of BOS-580 to the first patient in a Phase 2a clinical trial in individuals with nonalcoholic fatty liver disease and/or nonalcoholic steatohepatitis.